Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Moderna and Merck's personalized mRNA cancer vaccine (Intismeran) significantly reduced melanoma recurrence and spread when combined with Keytruda in a late-stage trial. The interim results beat expectations, sending Moderna's stock up nearly 90%. Analysts are cautiously optimistic but say full data, overall survival results, and manufacturing scalability will be key to determining its true clinical and commercial value.
Moderna and Merck's personalized mRNA cancer vaccine, Intismeran, significantly reduced the risk of melanoma recurrence and distant metastasis when combined with Merck's blockbuster immunotherapy Keytruda in a late-stage trial. The interim results were statistically significant, meaningfully exceeding investor expectations and sending Moderna's shares soaring nearly 90%, with Merck gaining 10%.
Analysts are encouraged but urge caution. While the trial's positive readout confirms the therapy works, key details — including recurrence-free survival hazard ratios, stage-specific analyses, and overall survival data — have yet to be released. Manufacturing personalized vaccines at scale also remains a complex and potentially costly challenge.
Key Takeaways:
Why it matters: This is a landmark moment for personalized mRNA oncology — if the full data holds up, it could reshape how advanced melanoma is treated and validate a broader platform for cancer vaccines.
